Last reviewed · How we verify
HRS-1780
At a glance
| Generic name | HRS-1780 |
|---|---|
| Sponsor | Shandong Suncadia Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease (PHASE3)
- A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism (PHASE2)
- Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease (PHASE2)
- Study on Drug Interaction of HRS-1780 Tablets, Henagliflozin Tablets, Metformin Tablets and HRS-7535 Tablets in Healthy Human (PHASE1)
- Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects (PHASE1)
- Safety and Tolerance of Increased Doses of HRS-1780 Tablets in Healthy Subjects (PHASE1)
- Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HRS-1780 CI brief — competitive landscape report
- HRS-1780 updates RSS · CI watch RSS
- Shandong Suncadia Medicine Co., Ltd. portfolio CI